Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
AUTL
$1.895
$
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Next Earnings
2026-02-25
Beta
1.993
Average Volume
Market Cap
Last Dividend
CIK
0001730463
ISIN
US05280R1005
CUSIP
05280R100
CEO
Christian Martin Itin
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
647
IPO Date
2018-06-22
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Autolus Therapeutics to Participate in Upcoming Investor Conferences | LONDON and GAITHERSBURG, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in two upcoming investor conferences. | GlobeNewsWire | 2026-02-24 07:00:00 |
| Stock Traders Purchase Large Volume of Autolus Therapeutics Call Options (NASDAQ:AUTL) | Autolus Therapeutics PLC Sponsored ADR (NASDAQ: AUTL - Get Free Report) saw unusually large options trading activity on Monday. Stock traders acquired 2,496 call options on the stock. This is an increase of approximately 476% compared to the average daily volume of 433 call options. Autolus Therapeutics Price Performance NASDAQ: AUTL opened at $1.73 on Tuesday. The | Defense World | 2026-02-24 01:12:54 |
| Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives $8.33 Average Target Price from Brokerages | Autolus Therapeutics PLC Sponsored ADR (NASDAQ: AUTL - Get Free Report) has been assigned a consensus rating of "Hold" from the six analysts that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12 month target | Defense World | 2026-02-10 01:46:44 |
| Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | LONDON and GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Compensation Committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 113,650 American Depositary Shares, representing an equal number of ordinary shares, to 22 employees pursuant to the Company's 2025 Inducement Plan. | GlobeNewsWire | 2026-02-04 08:57:00 |
| New Strong Sell Stocks for January 30th | TSE, PAC and AUTL have been added to the Zacks Rank #5 (Strong Sell) List on January 30th, 2026. | Zacks Investment Research | 2026-01-30 07:10:17 |
| New Strong Sell Stocks for January 22nd | MHVYF, NFG and AUTL have been added to the Zacks Rank #5 (Strong Sell) List on January 22, 2026. | Zacks Investment Research | 2026-01-22 07:05:37 |
| Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026 | Company expects preliminary unaudited AUCATZYL® net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately $75 million for the full year of 2025 Autolus anticipates full year 2026 AUCATZYL® net product revenue of $120 million to $135 million Independent real-world AUCATZYL® data from ROCCA consortium confirm high level of clinical activity with favorable safety profile Focus for 2026 is: Driving AUCATZYL® top line growth Optimizing manufacturing operation to improve gross margin and innovating on next generation manufacturing platform Progressing the CATULUS, LUMINA and BOBCAT trials to expand the utility of obe-cel in pediatric hem-oncology and autoimmune indications LONDON and Gaithersburg, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced preliminary unaudited net product revenue from sales of AUCATZYL® (obecabtagene autoleucel; obe-cel) for the fourth quarter and full year of 2025. | GlobeNewsWire | 2026-01-12 07:00:00 |
| Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform | SOUTH SAN FRANCISCO, Calif. and LONDON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, and Cellares Corp, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Autolus will assess the feasibility of Cellares' Cell Shuttle platform to complement its commercial manufacturing operations at the Nucleus facility in Stevenage, UK. | GlobeNewsWire | 2026-01-06 09:00:00 |
| Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform | SOUTH SAN FRANCISCO, Calif. & LONDON--(BUSINESS WIRE)--Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, and Cellares Corp, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Autolus will assess the feasibility of Cellares' Cell Shuttle platform to complement its commercial manufacturing operations at the Nucleus facility in Stevenag. | Business Wire | 2026-01-06 09:00:00 |
| Perpetual Ltd Has $784,000 Position in Autolus Therapeutics PLC Sponsored ADR $AUTL | Perpetual Ltd lessened its holdings in shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ: AUTL) by 42.0% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 481,081 shares of the company's stock after selling 348,009 shares during the period. Perpetual Ltd owned approximately 0.18% of Autolus | Defense World | 2025-12-22 05:40:51 |
| Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025 | Autolus presented preliminary data from the Phase 1 CARLYSLE trial in patients with severe refractory systemic lupus erythematosus (srSLE) at ASH 2025. | GlobeNewsWire | 2025-12-08 16:05:00 |
| Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025 | Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of high-grade cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) observed, consistent with obe-cel's adult safety profile FELIX study data analyses highlight product cell phenotype and level of CAR T persistence at three months as potential predictors of long-term remission Real-world data independently collected by the ROCCA consortium during the US commercial launch of obe-cel were presented and show a high response rate and low levels of high-grade CRS and ICANS consistent with the clinical trial experience in the FELIX study LONDON and GAITHERSBURG, Md., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces presentation of preliminary data from the CATULUS Phase 1 trial of obe-cel in pediatric relapsed or refractory (r/r) B-ALL patients, as well as further insights from the registrational FELIX study in adult r/r B-ALL, at the American Society of Hematology (ASH) Annual Meeting. | GlobeNewsWire | 2025-12-08 08:35:00 |
| Cetera Investment Advisers Has $1.41 Million Position in Autolus Therapeutics PLC Sponsored ADR $AUTL | Cetera Investment Advisers raised its position in Autolus Therapeutics PLC Sponsored ADR (NASDAQ: AUTL) by 17.6% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 617,172 shares of the company's stock after purchasing an additional 92,300 shares during the period. Cetera Investment Advisers | Defense World | 2025-12-02 04:14:58 |
| Autolus Therapeutics Appoints Ryan Richardson to Board of Directors | LONDON and GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced the appointment of Ryan Richardson to the Company's Board of Directors. | GlobeNewsWire | 2025-12-01 07:00:00 |
| Why Is Autolus Therapeutics Stock Trading Higher On Tuesday? | The U.K.'s National Institute for Health and Care Excellence (NICE) published on Tuesday draft guidance recommending Autolus Therapeutics plc's (NASDAQ: AUTL) Aucatzyl (obecabtagene autoleucel, or obe-cel) for use in the National Health Service (NHS) for adult patients (≥26 years) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). | Benzinga | 2025-11-25 12:37:51 |
| NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹ | LONDON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the National Institute for Health and Care Excellence (NICE) has published draft guidance1 recommending AUCATZYL® (obecabtagene autoleucel, or “obe-cel”)2 for use in the National Health Service (NHS) in England and Wales as a treatment option for adult patients (≥26 years) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). AUCATZYL will be available through routine commissioning by the NHS. | GlobeNewsWire | 2025-11-25 04:00:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-13 | 2026-02-13 | View Filing |
| 424B3 | 2026-01-26 | 2026-01-26 | View Filing |
| 8-K | 2026-01-26 | 2026-01-26 | View Filing |
| 424B3 | 2026-01-12 | 2026-01-12 | View Filing |
| 8-K | 2026-01-12 | 2026-01-12 | View Filing |
| SC 13G/A | 2025-12-03 | 2025-12-03 | View Filing |
| 424B3 | 2025-12-02 | 2025-12-02 | View Filing |
| 8-K | 2025-12-02 | 2025-12-02 | View Filing |
| S-8 | 2025-11-18 | 2025-11-18 | View Filing |
| SC 13G | 2025-11-14 | 2025-11-14 | View Filing |
| SC 13G/A | 2025-11-14 | 2025-11-14 | View Filing |
| 424B3 | 2025-11-12 | 2025-11-12 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| SC 13G/A | 2025-10-06 | 2025-10-06 | View Filing |
| 424B3 | 2025-08-12 | 2025-08-12 | View Filing |
| 10-Q | 2025-08-12 | 2025-08-12 | View Filing |
| 8-K | 2025-08-12 | 2025-08-12 | View Filing |
| 424B3 | 2025-06-30 | 2025-06-30 | View Filing |
| 8-K | 2025-06-27 | 2025-06-27 | View Filing |
| SC 13G | 2025-06-25 | 2025-06-25 | View Filing |
| 8-K | 2025-06-02 | 2025-06-02 | View Filing |
| 424B3 | 2025-05-30 | 2025-05-30 | View Filing |
| 8-K | 2025-05-30 | 2025-05-30 | View Filing |
| EFFECT | 2025-05-16 | 2025-05-16 | View Filing |
| 424B3 | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13G/A | 2025-05-12 | 2025-05-12 | View Filing |
| S-1 | 2025-05-08 | 2025-05-08 | View Filing |
| 10-Q | 2025-05-08 | 2025-05-08 | View Filing |
| 8-K | 2025-05-08 | 2025-05-08 | View Filing |
| SC 13G/A | 2025-05-07 | 2025-05-07 | View Filing |
| 8-K | 2025-04-23 | 2025-04-23 | View Filing |
| SC 13G/A | 2025-04-04 | 2025-04-04 | View Filing |
| 8-K | 2025-04-03 | 2025-04-03 | View Filing |
| EFFECT | 2025-03-24 | 2025-03-24 | View Filing |
| POS AM | 2025-03-20 | 2025-03-20 | View Filing |
| 10-K | 2025-03-20 | 2025-03-20 | View Filing |
| POSASR | 2025-03-20 | 2025-03-20 | View Filing |
| 8-K | 2025-03-20 | 2025-03-20 | View Filing |
| 8-K | 2025-01-13 | 2025-01-13 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| S-8 | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| 10-Q | 2024-11-12 | 2024-11-12 | View Filing |
| SC 13G | 2024-11-12 | 2024-11-12 | View Filing |
| 8-K | 2024-11-12 | 2024-11-12 | View Filing |
| 8-K | 2024-11-12 | 2024-11-12 | View Filing |
| SC 13G | 2024-11-08 | 2024-11-08 | View Filing |
| SC 13D/A | 2024-10-25 | 2024-10-25 | View Filing |
| 8-K | 2024-09-26 | 2024-09-26 | View Filing |
| 8-K | 2024-09-19 | 2024-09-19 | View Filing |
| 8-K | 2024-09-13 | 2024-09-13 | View Filing |
| 10-Q | 2024-08-08 | 2024-08-08 | View Filing |
| 8-K | 2024-08-08 | 2024-08-08 | View Filing |
| 8-K | 2024-06-28 | 2024-06-28 | View Filing |
| 8-K | 2024-06-05 | 2024-06-05 | View Filing |
| 8-K | 2024-06-03 | 2024-06-03 | View Filing |
| SC 13D/A | 2024-05-21 | 2024-05-21 | View Filing |
| 10-Q | 2024-05-17 | 2024-05-17 | View Filing |
| 8-K | 2024-05-17 | 2024-05-17 | View Filing |
| NT 10-Q | 2024-05-13 | 2024-05-13 | View Filing |
| 8-K | 2024-05-13 | 2024-05-13 | View Filing |
| 8-K | 2024-04-01 | 2024-04-01 | View Filing |
| S-3ASR | 2024-03-28 | 2024-03-28 | View Filing |
| SC 13D/A | 2024-03-25 | 2024-03-25 | View Filing |
| 10-K | 2024-03-21 | 2024-03-21 | View Filing |
| 8-K | 2024-03-21 | 2024-03-21 | View Filing |
| 8-K/A | 2024-03-15 | 2024-03-15 | View Filing |
| 8-K | 2024-03-14 | 2024-03-14 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Williams PercentR Strategy | 82.40% | 1 | 387 | 0.05 | 0.16 | 82.17 |
| Larry Williams PercentR Strategy | 60.33% | 1.02 | 190 | 0.05 | 0.14 | 60.1 |
| Neural Forcast | 35.30% | 1 | 919 | 0.01 | 0.03 | 35.08 |
| xxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxxx | xxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxx% | x | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | x | xxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |